Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2125006 | 1.00 | NPSR1 (0.32) | NPSR1MAPTKMT2ACYP4F2CYP4A11 | |
| SCHEMBL20221547 | 0.76 | NPSR1 (0.34) | NPSR1MAPT | |
| SCHEMBL7458948 | 0.70 | NPSR1 (0.34) | NPSR1MAPT | |
| SCHEMBL9853458 | 0.68 | LMNA (0.38) | NPSR1MAPT | |
| SCHEMBL7349981 | 0.67 | LMNA (0.32) | KMT2A | |
| SCHEMBL2123962 | 0.67 | CHRM2 (0.41) | — | |
| SCHEMBL15114584 | 0.67 | CHRM2 (0.41) | — | |
| SCHEMBL4876100 | 0.66 | NPSR1 (0.32) | NPSR1MAPT | |
| SCHEMBL4179515 | 0.66 | SLC6A9 (0.36) | NPSR1MAPT | |
| SCHEMBL14343316 | 0.64 | TSHR (0.50) | MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
| EP-2391628-A1 | 2-AZA-BICYCLOÝ2.2.1¨HEPTANE COMPOUNDS AND USES THEREOF | AstraZeneca AB (SE) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010087762-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010087762-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | SLC1A2, B4GALT1, SLC6A1 | NPSR1 761/4885MAPT 219/4885KMT2A 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.